KANGHUI PHARMACEUTICAL(SH:603139) Zheng Quan Ri Bao·2025-10-29 23:17Core Viewpoint - The company is undergoing significant changes, including a capital increase for its wholly-owned subsidiary, Beijing Kanghui Zhichuang Technology Co., Ltd., and addressing financial challenges related to its subsidiary, Shaanxi Youbang Biomedical Technology Co., Ltd. [11][67] Financial Data - The company plans to increase the registered capital of Kanghui Zhichuang from 10 million RMB to 100 million RMB by investing 90 million RMB [11][13] - The financial data for the first three quarters of 2025 has been disclosed, with specific revenue categories and regional performance yet to be detailed [64][65] Corporate Governance - The sixth board of directors has completed its re-election, with changes in the controlling shareholder and actual controllers [5] - The board meeting held on October 29, 2025, approved the capital increase and other significant resolutions [24][28] Subsidiary Operations - Kanghui Zhichuang, established in May 2025, is in its early stages of business development and does not significantly impact the company's overall performance [11][15] - Shaanxi Youbang has ceased operations and is seeking bankruptcy reorganization due to its inability to repay debts, which poses a risk to the company's financial health [67][69] Investment and Risk Management - The company is taking steps to enhance the financial strength of its subsidiaries while managing risks associated with potential losses from Shaanxi Youbang [18][75] - The company has recognized a bad debt provision of 120.9 million RMB related to Shaanxi Youbang, which will reduce its net profit for the first nine months of 2025 by 59.2 million RMB [60][62]